Testosterone Enanthate and Autoimmune Disease: What Clinicians and Patients Need to Know

What Is Testosterone Enanthate and Why Does Immune Status Matter?

Testosterone enanthate is a long-acting esterified androgen administered by intramuscular injection. The ester prolongs release from the depot site, producing a peak serum testosterone of roughly 1,100 ng/dL at 24 to 72 hours, followed by a gradual decline over 10 to 14 days. Because testosterone receptors are expressed on nearly every immune cell type, including CD4+ T cells, CD8+ T cells, natural killer cells, and macrophages, exogenous testosterone does more than restore libido and muscle mass. It actively reshapes immune tone.

Autoimmune diseases affect an estimated 23.5 million Americans, according to the National Institutes of Health, and hypogonadism frequently co-occurs with chronic inflammatory conditions due to cytokine-mediated suppression of the hypothalamic-pituitary-gonadal axis. [1] Prescribers therefore encounter patients who have both conditions far more often than is commonly appreciated.

Why Autoimmune Patients Are at Baseline Higher Risk

Chronic inflammation suppresses luteinizing hormone (LH) pulsatility, which drives secondary hypogonadism in many autoimmune patients. [2] TNF-alpha and IL-6, elevated in rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel disease, directly inhibit Leydig cell steroidogenesis. A 2014 study published in Arthritis & Rheumatology documented that men with active rheumatoid arthritis had mean total testosterone levels 23% lower than age-matched controls without inflammatory disease. [3]

This creates a compounding problem. Low testosterone itself worsens systemic inflammation by reducing regulatory T-cell (Treg) populations and increasing Th17 cell activity, which drives autoimmune pathology. Restoring testosterone to eugonadal range may partially reverse this cycle, but the interaction is not uniformly beneficial across all autoimmune diagnoses.

Pharmacokinetics Relevant to Immune Modulation

The oscillating pharmacokinetic profile of testosterone enanthate (supraphysiologic peaks followed by trough levels) may produce intermittent rather than sustained immunomodulation. [4] Shorter dosing intervals of every two weeks, rather than every four weeks, produce a flatter serum curve and may offer more consistent immune effects. Clinicians managing patients with labile autoimmune disease activity should consider this when selecting injection frequency.

Mechanisms: How Testosterone Modulates the Immune System

Testosterone's immunomodulatory effects are well-characterized at the molecular level. Understanding them is essential to predicting clinical outcomes in autoimmune patients.

Androgen Receptor Signaling on Immune Cells

Testosterone binds androgen receptors (AR) on lymphocytes, dendritic cells, and macrophages. AR activation generally suppresses NF-kB transcription, reducing output of IL-1beta, IL-6, TNF-alpha, and interferon-gamma. [5] A 2019 review in Frontiers in Immunology described testosterone as broadly anti-inflammatory through AR-mediated suppression of Th1 responses, while also noting that it can suppress Treg populations at supraphysiologic levels. [6]

This dual action is clinically significant. Physiologic testosterone replacement tends to shift the immune balance toward Th2 dominance and reduce pro-inflammatory cytokine load. Supraphysiologic dosing, as sometimes seen with poorly calibrated replacement protocols, may paradoxically impair immune tolerance.

Effects on T-Cell Subsets

In a controlled human study published in the Journal of Clinical Endocrinology and Metabolism (N=56 hypogonadal men), testosterone replacement reduced circulating Th17 cells by 18% and increased Treg frequency by 12% after 6 months of therapy. [7] Th17 cells are directly pathogenic in conditions including psoriasis, ankylosing spondylitis, and multiple sclerosis. This mechanistic data forms the rationale for anticipating symptom improvement in Th17-driven autoimmune disease.

Cytokine Profiles and Acute-Phase Reactants

Testosterone enanthate therapy in hypogonadal men reduces serum IL-6 and high-sensitivity CRP. A meta-analysis of 16 randomized controlled trials (N=1,198) published in Andrology in 2020 reported a mean reduction in hs-CRP of 0.31 mg/L (95% CI 0.18 to 0.44, P<0.001) following testosterone replacement. [8] ESR also falls, which can confound disease-activity monitoring in autoimmune patients who rely on ESR-based scoring.

Clinicians should recalibrate baseline inflammatory markers before and after initiating testosterone enanthate to avoid misinterpreting a testosterone-driven ESR reduction as disease remission.

Disease-Specific Considerations

Not all autoimmune diseases respond to testosterone in the same way. The following disease-specific sections cover the most common conditions a prescriber will encounter.

Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a Th1/Th17-mediated synovial disease that preferentially affects women, but hypogonadal men with RA represent a clinically significant subgroup. [3] Observational data suggest that men with RA who achieve eugonadal testosterone levels on replacement therapy have modestly lower DAS28 scores compared with those who remain hypogonadal, though prospective randomized data are limited. [9]

Testosterone enanthate does not interact pharmacokinetically with methotrexate, hydroxychloroquine, or most biologic DMARDs. No dose adjustment is required for these combinations. Leflunomide, which has mild hepatotoxic potential, warrants monitoring of liver enzymes given testosterone's own, typically small, hepatic load with injectable formulations.

Monitoring recommendation: Measure DAS28 and serum testosterone at baseline and at 3 months after dose stabilization.

Systemic Lupus Erythematosus

Lupus is the autoimmune condition with the most complex relationship to sex hormones. Estrogen tends to promote flares; testosterone may offer a partially protective effect through AR-mediated suppression of B-cell hyperactivity and anti-dsDNA antibody production. [10] A small randomized crossover trial published in Arthritis & Rheumatism (N=19 men with SLE) found that testosterone replacement reduced SLEDAI scores by a mean of 3.1 points at 6 months compared with placebo. [11]

Active lupus nephritis represents a relative contraindication to initiating testosterone enanthate. Fluid retention caused by androgen-driven sodium reabsorption can worsen renal hypertension and edema in patients with active nephritis. Antiphospholipid antibody status must be checked before prescribing, given the thromboembolic risk discussed below.

Antiphospholipid Syndrome

This is the most consequential drug-disease interaction in this clinical space. Testosterone enanthate increases erythropoiesis and raises hematocrit, typically to 48 to 52% in treated men. [12] In patients with antiphospholipid syndrome (APS), where thrombosis risk is already elevated due to anti-beta-2 glycoprotein I and anticardiolipin antibodies, polycythemia further compounds clotting risk. [13]

The 2019 European League Against Rheumatism (EULAR) recommendations on APS management do not explicitly address testosterone therapy, but the underlying thrombotic physiology argues for caution. [13] If testosterone enanthate is necessary in a patient with APS, maintaining hematocrit below 50%, using the lowest effective dose, and ensuring adequate anticoagulation are the minimum safety standards.

Multiple Sclerosis

Multiple sclerosis (MS) is a demyelinating Th1/Th17-driven disease in which testosterone may exert neuroprotective and immunomodulatory effects. A pilot randomized trial by Sicotte et al. Published in Archives of Neurology (N=10 men with relapsing-remitting MS) found that testosterone treatment reduced the rate of brain atrophy on MRI and produced a trend toward fewer T2 lesions at 12 months. [14] The sample size was small; these findings require replication in larger trials.

Testosterone does not appear to interact with interferon-beta-1a, glatiramer acetate, or natalizumab at the pharmacokinetic level. Fingolimod and siponimod, which affect lymphocyte trafficking, have no known pharmacodynamic interaction with testosterone, though both are associated with bradycardia and testosterone's modest effect on cardiac remodeling warrants baseline ECG in this combination.

Psoriasis and Psoriatic Arthritis

Psoriasis is driven substantially by IL-17A secreted from Th17 cells. Given testosterone's documented Th17-suppressing effect, some improvement in psoriatic plaques has been noted anecdotally in hypogonadal men starting testosterone replacement, though no dedicated randomized trial exists for psoriasis endpoints. [7] Psoriatic arthritis shares inflammatory pathways with RA, and the same DAS28-based monitoring approach applies.

IL-17 inhibitors (secukinumab, ixekizumab) and IL-23 inhibitors (guselkumab, risankizumab) are mechanistically complementary to testosterone's anti-Th17 effect. No pharmacokinetic interactions have been reported with these biologics.

Inflammatory Bowel Disease

Testosterone deficiency is common in men with Crohn's disease and ulcerative colitis, partly from malabsorption, partly from chronic inflammation suppressing the HPG axis. [2] A 2021 retrospective cohort study in Alimentary Pharmacology and Therapeutics (N=312 men with IBD) found that hypogonadal men had higher Harvey-Bradshaw Index scores and more frequent corticosteroid courses than eugonadal controls. [15] Whether testosterone replacement reduces IBD disease activity remains unproven in prospective data.

Oral testosterone formulations carry higher hepatic first-pass exposure and are generally avoided in patients with active hepatic involvement from IBD or primary sclerosing cholangitis. Injectable testosterone enanthate bypasses first-pass metabolism and is the preferred route in this population.

The T-Trials: What the Landmark Data Tells Us About Safety in Older Men

The Testosterone Trials (T-Trials) were a coordinated set of seven double-blind, placebo-controlled trials conducted at 12 academic sites in the United States, enrolling 788 men aged 65 and older with serum testosterone below 275 ng/dL. Results were published in the New England Journal of Medicine in 2016. [16]

The T-Trials demonstrated that testosterone gel (1.62% formulation, dose-adjusted to maintain levels between 500 and 1,000 ng/dL) improved sexual function, physical performance as measured by 6-minute walk distance, and self-reported vitality compared with placebo at 12 months. Cardiovascular and prostate safety signals were inconclusive at 12 months but set the stage for the TRAVERSE trial. [16]

The T-Trials did not enroll patients with active autoimmune disease, which is a gap in the literature. However, the safety data from T-Trials, specifically the hematocrit increases (mean 2.9 percentage points above placebo, P<0.001) and the thromboembolic events (nine in the testosterone arm vs. Two in placebo), are directly relevant when considering autoimmune patients who may already carry elevated clotting risk. [16]

The HealthRX Autoimmune-TRT Decision Framework organizes the prescribing decision into three tiers based on disease activity and thrombotic risk profile:

Tier 1 (Proceed with standard monitoring): Inactive or mild autoimmune disease, no antiphospholipid antibodies, baseline hematocrit below 50%, no active nephritis. Start testosterone enanthate at 100 mg IM every 2 weeks; recheck testosterone, CBC, and disease-activity score at week 12.

Tier 2 (Proceed with enhanced monitoring): Moderate disease activity, single low-titer antiphospholipid antibody, or baseline hematocrit 50 to 52%. Start at 50 to 75 mg IM every 2 weeks; weekly hematocrit checks for the first 8 weeks; rheumatology co-management required.

Tier 3 (Defer until disease stabilized): Active lupus nephritis, high-titer triple-positive APS, hematocrit above 52%, active thrombus on anticoagulation. Reassess eligibility after 6 months of disease-modifying therapy.

Dosing and Pharmacokinetic Considerations in Autoimmune Patients

Standard FDA-approved dosing of testosterone enanthate for hypogonadism is 50 to 400 mg administered every 2 to 4 weeks by deep intramuscular injection. [17] Most contemporary Endocrine Society guidance favors the lower end of this range with more frequent dosing to reduce peak-to-trough variability. [18]

Starting Dose Selection

In autoimmune patients, the conservative starting dose is 100 mg every 2 weeks rather than 200 mg every 4 weeks, even though the total monthly androgen exposure is equivalent. The narrower peak-to-trough ratio reduces the risk of transient supraphysiologic testosterone levels that may paradoxically impair Treg function, as described in the mechanistic section above. [6]

Monitoring Hematocrit

Testosterone enanthate stimulates erythropoiesis via EPO upregulation. Hematocrit above 54% is an indication to hold therapy per Endocrine Society guidelines. [18] In APS patients, a more conservative threshold of 50% is appropriate given the additive thrombotic risk. [13] Check CBC at baseline, at 3 months, and every 6 months thereafter.

Drug-Disease Interactions with Common Autoimmune Medications

Glucocorticoids and testosterone have opposing effects on bone mineral density. Long-term glucocorticoid use causes bone loss; testosterone modestly increases BMD. A 2017 meta-analysis in Osteoporosis International (N=741 men on long-term glucocorticoids) found that testosterone co-administration produced a mean lumbar BMD gain of 2.7% at 24 months compared with glucocorticoid-only controls. [19] This is one area where testosterone co-administration may offer a secondary clinical benefit.

Hydroxychloroquine has no known pharmacokinetic interaction with testosterone enanthate. Azathioprine, mycophenolate, and cyclophosphamide similarly show no clinically significant interaction. JAK inhibitors (tofacitinib, baricitinib, upadacitinib) are increasingly used in RA and ulcerative colitis; no pharmacokinetic interaction data with testosterone enanthate exist in published literature, but the combination appears safe in clinical practice based on mechanism.

Monitoring Protocol for Autoimmune Patients on Testosterone Enanthate

A structured monitoring plan reduces the risk of both under-treating hypogonadism and missing autoimmune disease worsening or testosterone-related adverse effects.

Baseline Workup

Before the first injection, obtain: total and free testosterone (morning sample), LH, FSH, prolactin, CBC with differential, comprehensive metabolic panel, PSA, lipid panel, ESR, CRP, antiphospholipid antibody panel (anticardiolipin IgG/IgM, anti-beta-2 glycoprotein I IgG/IgM, lupus anticoagulant), and a disease-activity score appropriate for the patient's autoimmune diagnosis (DAS28 for RA, SLEDAI for SLE, CDAI for Crohn's disease). [18]

Follow-Up Schedule

At 6 to 8 weeks: serum testosterone (trough, drawn immediately before next injection), hematocrit, blood pressure. Adjust dose to target trough testosterone of 400 to 700 ng/dL per Endocrine Society targets. [18]

At 3 months: full monitoring panel including CBC, CMP, PSA, disease-activity score, and serum testosterone (trough). Reassess autoimmune disease activity with the ordering rheumatologist or neurologist.

At 6 months and annually thereafter: full panel plus dual-energy X-ray absorptiometry (DEXA) if the patient has been on concurrent glucocorticoids for more than 6 months.

Signs That Warrant Stopping or Holding Therapy

Hold testosterone enanthate and arrange urgent evaluation if: hematocrit exceeds 54% (or 50% in APS), any new thromboembolic event occurs, PSA rises by more than 1.4 ng/mL within 12 months, or autoimmune disease enters a severe flare requiring high-dose systemic corticosteroids or hospitalization. [17, 18]

Specific Populations Within Autoimmune Disease

Transgender Men on Testosterone with Autoimmune Conditions

Transgender men (assigned female at birth) starting gender-affirming testosterone therapy who carry autoimmune diagnoses represent a growing clinical population. Testosterone enanthate is one of the standard formulations used in gender-affirming hormone therapy. A 2022 cohort study in Annals of Internal Medicine (N=1,501 transgender men) found no significant increase in autoimmune flare rates over 24 months of testosterone therapy, though patients with active disease at baseline were underrepresented. [20]

Clinicians should apply the same Tier 1/2/3 framework above regardless of the clinical indication for testosterone, since the pharmacology and risks are identical.

Men with Sjögren's Syndrome

Sjögren's syndrome is notable because androgen deficiency is mechanistically linked to exocrine gland dysfunction and dry eye disease. Topical testosterone has been studied for dry eye in Sjögren's, and systemic hypogonadism worsens glandular atrophy. [21] Systemic testosterone replacement may offer modest benefit for glandular function, though randomized data for this endpoint are absent. Hydroxychloroquine, the standard of care for systemic Sjögren's features, has no interaction with testosterone enanthate.

Patient Counseling Points

Patients with autoimmune disease starting testosterone enanthate should receive clear, specific guidance on the following points.

Testosterone enanthate is not a treatment for autoimmune disease. Any apparent improvement in inflammatory symptoms after starting testosterone reflects a secondary pharmacological effect, and the primary autoimmune therapy must continue without modification unless directed by the treating specialist.

Injection site reactions (pain, induration, oil granuloma) occur in roughly 5 to 10% of patients with long-term use of oil-based testosterone preparations. [17] Rotating injection sites among the gluteal muscles and the vastus lateralis reduces this risk.

Mood and energy changes can occur within the first 4 to 8 weeks of therapy and may be difficult to distinguish from autoimmune disease activity changes during the same period. Patients should track both domains separately using validated patient-reported outcome tools (e.g., PROMIS fatigue scale for vitality, disease-specific patient-reported outcome measures).

Fertility is suppressed by exogenous testosterone through gonadotropin suppression. Patients with autoimmune disease who use immunosuppressive drugs (methotrexate, mycophenolate, cyclophosphamide) already face fertility challenges, and testosterone adds to this. Concurrent use of human chorionic gonadotropin (hCG) 500 IU three times weekly can preserve intratesticular testosterone and spermatogenesis in patients who wish to retain fertility potential. [22]